Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR): 3 pipeline candidates · 2 upcoming catalysts · ~27 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
26.7 months
D/E -2.50
Lead: Approved
3 candidates
2 upcoming, next in ~5115d
0 buys · 4 sells (180d)
A transparent, data-derived signal for Esperion Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$814.3M
Cash
$156.2M
Quarterly Burn
$27.7M
Runway
26.7 mo
Revenue
$80.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| bempedoic acid/ezetimibe 180 mg-10 mg | Phase 4 |
| nexletol | Approved |
| nexlizet | Approved |
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
207
Total value held
$515.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 20,867,520 | $57.2M |
| blackrock, inc. | 17,852,427 | $48.9M |
| wasatch advisors lp | 15,768,897 | $43.2M |
| two seas capital lp | 11,394,833 | $31.2M |
| orbimed advisors llc | 10,570,300 | $29.0M |
| two sigma investments, lp | 9,458,779 | $25.9M |
| marshall wace, llp | 7,075,083 | $19.4M |
| state street corp | 7,055,794 | $19.3M |
| d. e. shaw & co., inc. | 6,540,785 | $17.9M |
| geode capital management, llc | 5,955,739 | $16.3M |
Showing top 10 of 207 institutional holders of Esperion Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Esperion Therapeutics, Inc.'s pipeline?
Esperion Therapeutics, Inc. (ESPR) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Esperion Therapeutics, Inc.'s lead drug candidate?
Esperion Therapeutics, Inc.'s most advanced tracked candidate is bempedoic acid/ezetimibe 180 mg-10 mg (Phase 4) for Healthy Lactating Women.
What is Esperion Therapeutics, Inc.'s next catalyst?
Esperion Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: NEXLETOL" — expected June 19, 2040.
What is Esperion Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Esperion Therapeutics, Inc. has approximately 26.7 months of cash runway.
What is Esperion Therapeutics, Inc.'s market capitalization?
Esperion Therapeutics, Inc.'s market capitalization is approximately $814.3M.
Get the full picture on Esperion Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.